These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25895887)

  • 1. Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease.
    Concannon RM; Okine BN; Finn DP; Dowd E
    Exp Neurol; 2015 Jul; 269():133-41. PubMed ID: 25895887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease.
    Concannon RM; Okine BN; Finn DP; Dowd E
    Exp Neurol; 2016 Sep; 283(Pt A):204-12. PubMed ID: 27317300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease.
    Gómez-Gálvez Y; Palomo-Garo C; Fernández-Ruiz J; García C
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():200-8. PubMed ID: 25863279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB
    Navarro G; Borroto-Escuela D; Angelats E; Etayo Í; Reyes-Resina I; Pulido-Salgado M; Rodríguez-Pérez AI; Canela EI; Saura J; Lanciego JL; Labandeira-García JL; Saura CA; Fuxe K; Franco R
    Brain Behav Immun; 2018 Jan; 67():139-151. PubMed ID: 28843453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of α-Synuclein in the Rat Brain.
    Kelly R; Bemelmans AP; Joséphine C; Brouillet E; McKernan DP; Dowd E
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.
    Walsh S; Mnich K; Mackie K; Gorman AM; Finn DP; Dowd E
    Brain Res Bull; 2010 Apr; 81(6):543-8. PubMed ID: 20097273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.
    Walsh S; Finn DP; Dowd E
    Neuroscience; 2011 Feb; 175():251-61. PubMed ID: 21145947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
    García C; Palomo-Garo C; García-Arencibia M; Ramos J; Pertwee R; Fernández-Ruiz J
    Br J Pharmacol; 2011 Aug; 163(7):1495-506. PubMed ID: 21323909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat.
    Hoban DB; Connaughton E; Connaughton C; Hogan G; Thornton C; Mulcahy P; Moloney TC; Dowd E
    Brain Behav Immun; 2013 Jan; 27(1):91-100. PubMed ID: 23044176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
    Silverdale MA; McGuire S; McInnes A; Crossman AR; Brotchie JM
    Exp Neurol; 2001 Jun; 169(2):400-6. PubMed ID: 11358453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.
    Han QW; Yuan YH; Chen NH
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109745. PubMed ID: 31442553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
    Fernández-Ruiz J; Romero J; Ramos JA
    Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease.
    Navarrete F; García-Gutiérrez MS; Aracil-Fernández A; Lanciego JL; Manzanares J
    Neurotherapeutics; 2018 Apr; 15(2):459-469. PubMed ID: 29352424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-course of striatal Toll-like receptor expression in neurotoxic, environmental and inflammatory rat models of Parkinson's disease.
    McCabe K; Concannon RM; McKernan DP; Dowd E
    J Neuroimmunol; 2017 Sep; 310():103-106. PubMed ID: 28778432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.
    Palazuelos J; Aguado T; Pazos MR; Julien B; Carrasco C; Resel E; Sagredo O; Benito C; Romero J; Azcoitia I; Fernández-Ruiz J; Guzmán M; Galve-Roperh I
    Brain; 2009 Nov; 132(Pt 11):3152-64. PubMed ID: 19805493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide.
    Loría F; Petrosino S; Mestre L; Spagnolo A; Correa F; Hernangómez M; Guaza C; Di Marzo V; Docagne F
    Eur J Neurosci; 2008 Aug; 28(4):633-41. PubMed ID: 18657182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of CB₂ receptors in human nigral neurons that degenerate in Parkinson's disease.
    García MC; Cinquina V; Palomo-Garo C; Rábano A; Fernández-Ruiz J
    Neurosci Lett; 2015 Feb; 587():1-4. PubMed ID: 25481767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.
    Hunter RL; Dragicevic N; Seifert K; Choi DY; Liu M; Kim HC; Cass WA; Sullivan PG; Bing G
    J Neurochem; 2007 Mar; 100(5):1375-86. PubMed ID: 17254027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different expression and function of the endocannabinoid system in human epicardial adipose tissue in relation to heart disease.
    Cappellano G; Uberti F; Caimmi PP; Pietronave S; Mary DA; Dianzani C; Micalizzi E; Melensi M; Boldorini R; Nicosia G; Crosio E; Chiocchetti A; Aina F; Prat M; Dianzani U; Vacca G; Ariatti C; Grossini E
    Can J Cardiol; 2013 Apr; 29(4):499-509. PubMed ID: 22926037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid receptor subtypes 1 and 2 mediate long-lasting neuroprotection and improve motor behavior deficits after transient focal cerebral ischemia.
    Schmidt W; Schäfer F; Striggow V; Fröhlich K; Striggow F
    Neuroscience; 2012 Dec; 227():313-26. PubMed ID: 23069763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.